Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Jul 10, 2021 11:29am
144 Views
Post# 33526610

RE:RE:RE:Karmanos cancer institute starts THTX’s PDC program

RE:RE:RE:Karmanos cancer institute starts THTX’s PDC program Company's approach evidently  so far has been not to disclose any information regarding the trial, I and others ask questions about the trial's process during the webinar with no luck. For THTX with a market cap well undervalued and few investors following the company I believe that's not the right strategy, I think they should attend many conferences explaining their programs and the progress so far. They need to to open up and proactively market their programs to close the gap in terms of awareness, market perception, size of their audience and valuation between THTX and the comps.
That's to me the plan A, B, C.. Now they stated they have a new plan and the new job posting looking for a communication manager again to me is an indication that they mean the business, but they need to speed things up imo.


Bucknelly21 wrote:
scarlet1967 wrote: Dr. Winer's bio below, it seems like he has been in charge of multiple trials in various phases.

https://www.karmanos.org/karmanos/karmanos-physician-directory/winer-ira-9376





scarlet1967 wrote: One has to see this as an encouraging news.
https://www.karmanos.org/karmanos/find-a-karmanos-clinical-trial/150

 
I think it's a positive for sure but why do we always have to learn things from everyone but the company 



<< Previous
Bullboard Posts
Next >>